Gilead Cuts 2020 Sales Outlook As COVID-19 Drug Remdesivir Falls Short

Gilead Sciences Inc on Wednesday cut its 2020 revenue forecast, citing lowerthanexpected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with COVID19.

from Top Business News- News18.com https://ift.tt/3owbcoF

• Tweet
• Share
• Share
• Share
• Share